GlassScriptPhysician profile
Donna L Betz
NPI 1942401005
$4,542.11
in general payments reported to CMS, 2019-2025
37 companies · $1,296 in 2025
The $1,296 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $167 · 2022: $87.64 · 2023: $1,213 · 2024: $1,424 · 2025: $1,296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,933.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.94 | 2022-2025 | Vraylar |
| Lilly USA, LLC | $551.83 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $467.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $447.57 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $433.31 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $356.61 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.39 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $173.30 | 2024-2025 | Rexulti |
| Amgen INC. | $162.65 | 2019-2025 | Repatha, Otezla, Otezla |
| Axsome Therapeutics, INC. | $162.36 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $105.02 | 2024-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $103.97 | 2019-2025 | Trintellix |
| Dynavax Technologies Corporation | $81.06 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $70.34 | 2025 | Voquezna |
| Exact Sciences Corporation | $60.01 | 2023-2025 | Cologuard Collection Kit |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Betz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.